A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 319
- Registration Number
- NCT05628311
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
A Study of [14C]IBI351 in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- Drug: [14C] IBI351
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05626179
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
A Study of IBI362 in Participants With Obesity or Overweight
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 610
- Registration Number
- NCT05607680
- Locations
- 🇨🇳
Xuancheng People's Hospital, Xuancheng, Anhui, China
🇨🇳Hebei Petro China Central Hospital, Langfang, Hebei, China
🇨🇳Luoyang Third People's Hospital, Luoyang, Henan, China
A Study of IBI362 in Participants With Type 2 Diabetes
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 731
- Registration Number
- NCT05606913
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijin, China
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
- Conditions
- Unresectable Cutaneous MelanomaMetastatic Cutaneous Melanoma
- Interventions
- Combination Product: Sintilimab + IBI110
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Registration Number
- NCT05572463
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of California San Francisco Medical Center, San Francisco, California, United States
🇦🇺Princess Victoria Hospital, Woolloongabba, Queensland, Australia
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT05504278
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Jilin, Changchun, China
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05497336
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of IBI353 (Orismilast) in Chinese Healthy Adults
- Conditions
- Healthy Subjects
- Interventions
- Drug: placeboDrug: IBI353 (Orismilast)
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05490316
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- Biological: IBI324
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05489718
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
A Study of IBI311 in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Biological: IBI311Biological: placebo
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05480579
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China